Pfizer, a US giant drug maker, has announced starting the medium to final stages of trials of an oral medicine which was designed to protect the human body against the infection with the Coronavirus.
The medicine was supposed to be used with those who actually caught the deadly virus.
The company indicated, over a statement quoted by the Hill, a US daily newspaper that specialized in news items related to US Congress, that its experts are still achieving more progress to detect the impact of the oral medicine after finishing the initiative trails and affirming its safety and absorbing it through the blood circulation.
Pfizer explained that over the coming period it will work to recruit 2660 persons who enjoy good health and live in a house with other persons infected with COVID-19.
Pfizer's statement added that people who will participate in trials will receive the oral medicine accompanied with a slight dose of "Ritonavir", a drug used to treat (Human Immunodeficiency Virus, HIV, or an alternative to it in order to remain the medicine of COVID-19 in the body for a longer time.
The participants in trials of the oral medicine will receive a daily dose for a period ranges from five to ten days.
The company mentioned that oral medicine works to thwart an enzyme needed by COVID-19 to produce new copies from it and to spread inside the human body.
The US company indicated that its new medicine aims to prevent infection with the Coronavirus and its accompanies symptoms throughout two weeks after exposure to the infection.
It made clear the medicine will be introduced to the participants as soon as the first symptoms appear on them or when they are certain that they are exposed to the virus without being admitted to the hospital.
Follow the latest news on Google News
